Table 1 Clinical characteristics of DLBCL patients in the GDPH and TCGA datasets (n = 124)
Variables | GDPH dataset, n (%)a | TCGA dataset, n (%)a | P value |
|---|---|---|---|
Number | 87 | 37 | Â |
Gender | 0.528 | ||
 Female | 44 (50.6) | 21 (56.8) |  |
 Male | 43 (49.4) | 16 (43.2) |  |
Age, years | 0.638 | ||
 Younger than 60 | 51 (58.6) | 20 (54.1) |  |
 Older than 60 | 36 (41.4) | 17 (45.9) |  |
Immunophenotype | NA | ||
 GCB | 24 (27.6) | – |  |
 Non-GCB | 46 (52.9) | – |  |
 Unclassified | 2 (2.3) | – |  |
 Unknown | 15 (17.2) | – |  |
Serum LDH level |  < 0.001 | ||
 Normal | 31 (35.6) | 12 (32.4) |  |
 Elevated | 56 (64.4) | 12 (32.4) |  |
 Unknown | 0 (0.0) | 13 (35.1) |  |
Extranodal involvement |  < 0.001 | ||
 0–1 | 47 (54.0) | 17 (45.9) |  |
 More than 1 | 40 (46.0) | 10 (27.0) |  |
 Unknown | 0 (0.0) | 10 (27.0) |  |
ECOG PS | NA | ||
 0–1 | 66 (75.9) | – |  |
 2–4 | 21 (24.1) | – |  |
Ann Arbor stage |  < 0.001 | ||
 I/II | 33 (37.9) | 21 (56.8) |  |
 III/IV | 54 (62.1) | 11 (29.7) |  |
 Unknown | 0 (0.0) | 5 (13.5) |  |
IPI score | NA | ||
 0–2 | 46 (52.9) | – |  |
 3–5 | 41 (47.1) | – |  |
DHL/DEL | – | NA | |
 Yes | 30 (34.5) | – |  |
 No | 57 (65.5) | – |  |
HBsAg | – | NA | |
 Positive | 17 (19.5) | – |  |
 Negative | 70 (80.5) | – |  |
Anti-HBc | – | NA | |
 Positive | 18 (20.7) | – |  |
 Negative | 69 (79.3) | – |  |
HBV-DNA | – | NA | |
 Positive | 10 (11.5) | – |  |
 Negative | 77 (88.5) | – |  |
Treatment | NA | ||
 R-CHOP | 74 (85.1) | – |  |
 BFM-90 | 1 (1.1) | – |  |
 Rituximab + Lenalidomide | 7 (8.0) | – |  |
 Radiation | 0 (0) | 6 (16.2) |  |
 Unknown | 5 (5.7) | 1 (2.7) |  |